Hjem
Caroline Benedicte Nitter Engens bilde
Foto:
Andrea Magugliani

Caroline Benedicte Nitter Engen

Postdoktor
  • E-postCaroline.Engen@uib.no
  • Telefon+47 932 01 700
  • Besøksadresse
    Parkveien 9
  • Postadresse
    Postboks 7805
    5020 BERGEN

Caroline Engen er postdoktor i Neuro-SysMed-senterets forskergruppe Philosophy of Neurodegeneration, ledet av Jan Reinert Karlsen ved SVT.

Vitenskapelig artikkel
  • Vis forfatter(e) (2021). Sex disparity in acute myeloid leukaemia with FLT3 internal tandem duplication mutations: implications for prognosis. Molecular Oncology. 2285-2299.
  • Vis forfatter(e) (2021). Reframing cancer: challenging the discourse on cancer and cancer drugs—a Norwegian perspective: Reframing Cancer. BMC Medical Ethics.
  • Vis forfatter(e) (2021). FLT3-ITD mutations in acute myeloid leukaemia – molecular characteristics, distribution and numerical variation. Molecular Oncology. 2300-2317.
  • Vis forfatter(e) (2019). Titrating complex mass cytometry panels. Cytometry Part A. 1-6.
  • Vis forfatter(e) (2016). Development of personalized molecular therapy for acute myeloid leukemia. Current Pharmaceutical Biotechnology. 20-29.
Vitenskapelig antologi/Konferanseserie
  • Vis forfatter(e) (2017). Cancer Biomarkers: Ethics, Economics and Society. Megaloceros Press.
Brev til redaktøren
  • Vis forfatter(e) (2021). Enhanced cognitive behaviour therapy (CBT-E) for severe and extreme anorexia nervosa in an outpatient eating disorder unit at a public hospital: a quality-assessment study. Journal of Eating Disorders. 5 sider.
Doktorgradsavhandling
  • Vis forfatter(e) (2020). Exploring the boundaries of precision haemato-oncology – The case of FLT3 length mutated acute myeloid leukaemia.
Poster
  • Vis forfatter(e) (2017). development of novel Highly Specific FLT3 Targeted Inhibitors for Combination or Sequential Therapy of Acute Myeloid Leukemia.
Fagartikkel
  • Vis forfatter(e) (2014). Targeted Therapy of FLT3 in Treatment of AML-Current Status and Future Directions. Journal of Clinical Medicine.
  • Vis forfatter(e) (2013). Målrettet behandling av akutt myelogen leukemi - hemmere mot FLT3 og andre kinaser viser vei. Best Practice.

Se fullstendig oversikt over publikasjoner i CRIStin.

Neuro-SysMed-senterets forskergruppe Philosophy of Neurodegeneration, ledet av Jan Reinert Karlsen ved SVT.